<?xml version="1.0" encoding="UTF-8"?>
<p>Pain and inflammation are another important dominant factor for mental and behavioural disarrays [
 <xref rid="B5-molecules-25-04737" ref-type="bibr">5</xref>]. Several neurotransmitters, including norepinephrine and serotonin have parallel expression pathways for both nociception and neuropsychiatric disorders [
 <xref rid="B6-molecules-25-04737" ref-type="bibr">6</xref>]. Thus, chronic pain and inflammation can contribute to developing anxiety-like complications [
 <xref rid="B7-molecules-25-04737" ref-type="bibr">7</xref>]. Some sedatives and hypnotic drugs are used to treat anxiety by persuading sleep inception. However, serious side effects like respiratory, digestive, immune system dysfunctions, physical dependence and tolerance are appearing due to regular use of currently obtainable sedative-hypnotic medications [
 <xref rid="B8-molecules-25-04737" ref-type="bibr">8</xref>]. Henceforth, it is extremely needed to develop a new sedative-hypnotic drug with less adverse effect to managing various psychiatric disorders.
</p>
